Login to Your Account



Pharma: Clinic Roundup


Friday, June 15, 2012
• Teva Pharmaceutical Industries Ltd., of Jerusalem, reported top-line data from the Phase III GALA (Glatiramer Acetate Low-Frequency Administration) trial testing 40 mg/1 ml glatiramer acetate (GA 40 mg/1 ml) injection administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription